Clinical pharmacology of the serotonin receptor agonist, zolmitriptan

Bibliography

• HAMEL E, SAXENA PR: 5-Hydroxytryptamine involvement in migraines. In: The Headaches (3rd Edition). Olesen J, Goadsby PJ, Ramadan NM, Tfelt-Hansen P, Welch KMA (Eds), Lippincott, Williams and Wilkins Publishers, Philadelphia, USA (2006):275-281.
   Web of Science ®Google Scholar
• FERRARI MD, SAXENA PR: 5-HT1 receptors in migraine pathophysiology and treatment. Eur. J. Neurol. (1995) 2:5-21.
   PubMedGoogle Scholar
• GOADSBY PJ: Serotonin 5-HT1B/1D receptor agonists in migraine: clinical pharmacology and its therapeutic implications. CNS Drugs (1998) 10(4):271-286.
   Web of Science ®Google Scholar
• HUMPHREY PPA: 5-Hydroxytryptamine and the pathophysiology of migraine. J. Neurol. (1991) 238:S38-S44.
   PubMed Web of Science ®Google Scholar
• RAPOPORT AM, BIGAL ME, TEPPER SJ, SHEFTELL FD: Zolmitriptan (Zomig©). Expert Rev. Neurother. (2004) 4(1):33-41.
   PubMedGoogle Scholar
• FRAZER A, HENSLER JULIE G: Serotonin. In: Basic Neurochemistry. Siegel GJ, Agranof BW, Albers RW, Fisher SK, Uhler MD (Eds), Lippincott, Williams and Wilkins Publishers, Philadelphia, USA (1999):263-292.
   Google Scholar
• WAEBER CHRISTIAN: Serotonin and other biogenic amines. In: The Headaches (3rd Edition). Olesen J, Goadsby PJ, Ramadan NM, Tfelt-Hansen P, Welch KMA (Eds), Lippincott, Williams and Wilkins Publishers, Philadelphia, USA (2006):143-149.
   Google Scholar
• GROENINK L, VAN BOAGAERT MJV, VAN DER GUGTEN J, OOSTING RS, OLIVIER B: 5-HT1A receptor and 5-HT1B receptor knockout mice in stress and anxiety paradigms. Behav. Pharmacol. (2003) 14(5-6):369-383.
   PubMed Web of Science ®Google Scholar
• DE HOON JNJM, WILLIGERS JM, TROOST J, STRUIJKER-BOUDIER HAJ, VAN BORTEL LMAB: Vascular effects of 5-HT1B/1D-receptor agonists in patients with migraine headaches. Clin. Pharmacol. Ther. (2000) 68:418-426.
   PubMed Web of Science ®Google Scholar
• FERRARI MD: 311C90: increasing the options for therapy with effective acute antimigraine 5-HT1B/1D-receptor agonists. Neurology (1997) 48(Suppl. 3):S21-S24.
   PubMed Web of Science ®Google Scholar
• MARTIN GR: Pre-clinical pharmacology of zolmitriptan (Zomig™); formerly 311C90, a centrally and peripherally acting5-HT1B/1D agonist for migraine. Cephalalgia (1997) 17(Suppl. 18):4-14.
   PubMed Web of Science ®Google Scholar
• WURCH T, COLPAERT FC, PAUWELS PJ: Chimeric receptor analysis of the ketanserin binding site in the human 5-hydroxytryptamine1D receptor: importance of the second extrracellular loop and fifth transmembrane domain in antagonist binding. Mol. Pharmacol. (1998) 54:1088-1096.
   PubMed Web of Science ®Google Scholar
• HUMPHREY PPA, FENIUK W, PERREN MJ, CONNOR HE, OXFORD AW: The pharmacology of the novel 5-HT1-like receptor agonist, GR43175. Cephalalgia (1989) 9(Suppl. 9):23-33.
   PubMed Web of Science ®Google Scholar
• MOSKOWITZ MA, CUTRER FM: Attacking migraine headache from beginning to end. Cephalalgia (1997) 49:1193-1195.
   Google Scholar
• GERAUD G, OLESEN J, PFAFFENRATH V et al.: Comparison of the efficacy of zolmitriptan and sumatriptan: issues in migraine trial design. Cephalalgia (2000) 20:30-38.
   PubMed Web of Science ®Google Scholar
• DAHLOF C: Clinical applications of new therapeutic deliveries in migraine. Neurology (2003) 61(8)(Suppl. 4):S31-S34.
   PubMed Web of Science ®Google Scholar
• YATES R, NAIRN K, DIXON R, SEABER E: Preliminary studies of the pharrmacokinetics and tolerability of zolmitriptan nasal spray in healthy volunteers. J. Clin. Pharmacol. (2002) 42:1237-1243.
   PubMed Web of Science ®Google Scholar
• ZINGMARK PH, YATES R, HEDLUND C, KAGEDAL M: True nasopharyngeal absorption of zolmitriptan following administration of zolmitriptan nasal spray. Eur. J. Neurol. (2003) 10(Suppl. 1):76.
   Web of Science ®Google Scholar
• MACGREGOR A: Management of migraine in general practice. Prescriber (1998) 19:49-70.
   Google Scholar
• GILLOTIN C, BAGNIS C, MARNET JP, PECK RW, DERAY G: No need to adjust the dose of 311C90 (zolmitriptan), a novel anti-migraine treatment, in patients with renal failure not requiring dialysis. Int. J. Clin. Pharmacol. Ther. (1997) 35(11):522-526.
   PubMed Web of Science ®Google Scholar
• ROLAN P: Potential drug interactions with the novel antimigraine compound zolmitriptan(Zomig©, 311C90). Cephalalgia (1997) 14(Suppl. 18):21-27.
   Google Scholar
• FERRARI MD, GOADSBY PJ, ROON KI, LIPTON RB: Triptans (serotonin, 5-HT1B/1D agonists) in migraine: detailed results and methods of a meta-analysis of 53 trials. Cephalalgia (2002) 22:633-658.
   PubMed Web of Science ®Google Scholar
• SEABER E, ON N, DIXON RM, GIBBENS M, LEAVENS WJ, LIPTROT J et al.: The absolute bioavailability and metabolic disposition of the novel antimigraine compound zolmitriptan (311C90). Br. J. Clin. Pharamacol. (1997) 43:579-587.
   PubMed Web of Science ®Google Scholar
• PALMER KJ, SPENCER CM: Zolmitriptan. CNS Drugs (1997) 7:468-478.
   Web of Science ®Google Scholar
• SEABER E, ON N, PHILIPS R, CHRUCHUS J, POSNER J, ROLAN P: The tolerability and pharmacokinetics of the novel antimigraine compound 311C90 in healthy male volunteers. Br. J. Clin. Pharmacol. (1996) 41:141-147.
   PubMed Web of Science ®Google Scholar
• VERONESE L, GILLOTIN C, MARION-GALLOIS R et al.: Lack of an interaction between oral dihydroergotamine and the novel antimigraine compound zolmitriptan (“Zomig”, 311C90) in healthy volunteers. Clin. Drug Invest. (1997) 14:217-220.
   Web of Science ®Google Scholar
• SYRETT NB, ABU-SHAKRA S, YATES R: Zolmitriptan nasal spray: advances in migraine treatment. Neurology (2003) 61(8)(Suppl. 4):S27-S30.
   PubMed Web of Science ®Google Scholar
• AURORA SK, KORI SH, BARRODALE P, MCDONALD SA, HASELEY D: Gastric stasis in migraine: more than just a paroxysmal abnormality during a migraine attack. Headache (2006) 46(1):57-63.
   PubMed Web of Science ®Google Scholar
• UEMURA N, ONISHI T, MITANIYAMA A et al.: Bioequivalence and rapid absorption of zolmitriptan nasal spray compared to oral tablets in healthy Japanese subjects. Clin. Drug Invest. (2005) 25(3):199-208.
   PubMed Web of Science ®Google Scholar
• SMITH DA, CLEARY EW, WATKINS S, HUFFMAN CS, DILZER SC, LASSETER KC: Pharmacokinetics and pharmacodynamics of zolmitriptan in patients with mild to moderate hypertension: a double-blind, placebo-controlled study. J. Clin. Pharmacol. (1998) 38(8):685-693.
   PubMed Web of Science ®Google Scholar
• DAHLOF C, DIENER HC, GOADSBY PJ et al.: Zolmitriptan, a 5-HT1B/1D receptor agonist for the acute oral treatment of migraine: a multicentre dose-range finding study. Eur. J. Neurol. (1998) 5:535-543.
   PubMed Web of Science ®Google Scholar
• CHARLESWORTH B, DOWSON AJ: Review of zolmitriptan and its clinical applications in migraine. Expert Opin. Pharmacother. (2002) 3(7):993-1005.
   PubMedGoogle Scholar
• PHYSICIANS' DESK REFERENCE: 60th Edition. Thomson, PDR, Montvale, NJ, USA (2006):714-722.
   Google Scholar
• LODER E, SILBERSTEIN SD, ABU-SHAKRA S et al.: Efficacy and tolerability of oral zolmitriptan in menstrually associated migraine: a randomized, prospective, parallel-group, double-blind, placebo-controlled study. Headache (2004) 44:120-130.
   PubMed Web of Science ®Google Scholar
• NEWMAN LC, LIPTON RB, LAY CL, SOLOMON S: A pilot study of oral sumatriptan as intermittent prophylaxis of menstruation-related migraine. Neurology (1998) 51:307-309.
   PubMed Web of Science ®Google Scholar
• NEWMAN L, MANNIX LK, LANDY S et al.: Naratriptan as short-term prophylaxis of menstrually associated migraine: a randomized double-blind, placebo-controlled study. Headache (2001) 41:248-256.
   PubMed Web of Science ®Google Scholar
• SILBERSTEIN SD, ELKIND AH, SHREIBER C, KEYWOOD C: A randomized trial of frovatriptan for the intermittent prevention of menstrual migraine. Neurology (2004) 63:261-269.
   PubMed Web of Science ®Google Scholar
• TUCHMAN M, HEE A, EMERIBE U: Oral zolmitriptan 2.5 mg demonstrates high efficacy and good tolerability in the prophylactic treatment of menstrual migraine headaches. Headache (2005) 45:771-772 (Abstract OR13).
   Google Scholar
• BRANDES J, MARCUS DA: Migraine management during pregnancy. In: Migraine in Women. Loder E, Marcus DA (Eds), BC Decker, Inc. Publishers, Hamilton, Ontario, USA (2004):112-121.
   Google Scholar
• OLESEN C, STEFFENSEN FH, SORENSEN HT, NIELSEN GL, OLSEN J: Pregnancy outcome following prescription for sumatriptan. Headache (2000) 40:20-24.
   PubMed Web of Science ®Google Scholar
• KALLEN B, LYGNER PE: Delivery outcome in women who used drugs for migraine during pregnancy with special reference to sumatriptan. Headache (2001) 41:351-356.
   PubMed Web of Science ®Google Scholar
• LINDER SL, DOWSON SJ: Zolmitriptan provides effective migraine relief in adolescents. Int. J. Clin. Pract. (2000) 54:466-469.
   PubMed Web of Science ®Google Scholar
• EVERS S, RAHMANN A, KRAEMER C et al.: Treatment of childhood migraine attacks with oral zolmitriptan and ibuprofen. Neurology (2006) 67:497-499.
   PubMed Web of Science ®Google Scholar
• LEWIS DW, WINNER P, HERSHEY AD et al.: Efficacy of zolmitriptan nasal spray in adolescent migraine. Pediatrics (2007) 120:390-396.
   PubMed Web of Science ®Google Scholar
• PECK RW, SEABER EJ, DIXON RM et al.: The pharmacodynamics and pharmacokinetics of the 5-HT1B/1D receptor agonist zolmitriptan in healthy young and elderly men and women. Clin. Pharmacol. Ther. (1998) 63:342-353.
   PubMed Web of Science ®Google Scholar
• SCHOENEN J, SAWYER J: Zolmitriptan (Zomig™, 311C90), a novel dual central and peripheral 5-HT1B/1D agonist: an overview of efficacy. Cephalalgia (1997) 17(Suppl. 18):28-40.
   PubMed Web of Science ®Google Scholar
• RAPOPORT AM, RAMADAN NM, ADELMAN JU et al.: Optimizing the dose of zolmitriptan (Zomig™, 311C90) for the acute treatment of migraine: a multicenter, double-blind, placebo-controlled, dose range-finding study. Neurology (1997) 49(5):1210-1218.
   PubMed Web of Science ®Google Scholar
• VISSER WH, KLEIN KB, COX RC, JONES D, FERRARI MD: 311C90, a new central and peripherally acting 5-HT1D receptor agonist in the acute oral treatment of migraine: a double-blind, placebo-controlled, dose-range finding study. Neurology (1996) 46(2):522-526.
   PubMed Web of Science ®Google Scholar
• SOLOMON GD, CADY RK, KLAPPER JA, EARL NL, SAPER JR, RAMADAN NM: Clinical efficacy and tolerability of 2.5 mg zolmitriptan for the acute treatment of migraine. Neurology (1997) 49(5):1219-1225.
   PubMed Web of Science ®Google Scholar
• TUCHMAN M, EDVINSSON L, GERAUD G, KORCZYN A, MAUSKOP A, PFAFFENRATH V: Zolmitriptan provides consistent migraine relief when used in the long-term. Curr. Med. Res. Opin. (1999) 15(4):272-281.
   PubMed Web of Science ®Google Scholar
• GERAUD G, OLESEN J, PFAFFENRATH V et al.: Comparison of the efficacy of zolmitriptan and sumatriptan: issues in migraine trial design. Cephalalgia (2000) 20:30-38.
   PubMed Web of Science ®Google Scholar
• GALLAGHER RM: Comparison of zolmitriptan and sumatriptan for the acute treatment of migraine. Cephalalgia (1999) 19:358.
   Web of Science ®Google Scholar
• BECKER WJ: Zolmitriptan versus sumatriptan comparison trial. Headache (2001) 41:321-323.
   PubMed Web of Science ®Google Scholar
• PASCUAL J, VEGA P, DIENER HC, ALLEN C, VRIJENS F, PATEL K: Comparison of rizatriptan 10 mg vs. zolmitriptan 2.5 mg in the acute treatment of migraine. Cephalalgia (2000) 20:455-461.
   PubMed Web of Science ®Google Scholar
• STEINER TJ, DIENER HC, MACGREGOR EA, SCHOENEN J, NUIRHEAD N, SIKES CR: Comparative efficacy of eletriptan and zolmitriptan in the acute treatment of migraine. Cephalalgia (2003) 23(10):942-952.
   PubMed Web of Science ®Google Scholar
• LODER E, FREITAG FG, ADELMAN J, PEARLMAN S, ABU-SHAKRA S: Pain-free rates with zolmitriptan 2.5 mg ODT in the acute treatment of migraine: results of a large double-blind placebo-controlled trial. Curr. Med. Res. Opin. (2005) 21(3):381-389.
   PubMed Web of Science ®Google Scholar
• DOWSON AJ, MACGREGOR EA, PURDY RA, BECKER WJ, GREEN J, LEVY SL: Zolmitriptan orally disintegrating tablet is effective in the acute treatment of migraine. Cephalalgia (2001) 22:101-106.
   Web of Science ®Google Scholar
• SPIERINGS ELH, RAPOPORT AM, DODICK DW, CHARLESWORTH B: Acute treatment of migraine with zolmitriptan 5 mg orally disintegrating tablet. CNS Drugs (2004) 18(15):1133-1141.
   PubMed Web of Science ®Google Scholar
• CHARLESWORTH BR: Migraine patients prefer the zolmitriptan orally disintegrating tablet formulation to the rizatriptan wafer tablet formulation: an assessment of taste and ease to use. Headache (2002) 43:332.
   Google Scholar
• DOWSON AJ, CHARLESWORTH BR: Patients with migraine prefer zolmitriptan orally disintegrating tablet to sumatriptan tablet conventional oral tablet. Int. J. Clin. Pract. (2003) 57(7):573-576.
   PubMed Web of Science ®Google Scholar
• CHARLESWORTH BR, DOWSON AJ, PURDY A, BECKER WJ, BOES-HANSEN S, FARKKILA M: Speed of onset and efficacy of zolmitriptan nasal spray in the acute treatment of migraine: a randomized, double-blind, placebo-controlled, dose-ranging study versus zolmitriptan tablet. CNS Drugs (2003) 17(9):653-667.
   PubMed Web of Science ®Google Scholar
• DODICK D, BRANDES J, ELKIND A, MATHEW N, RODICHOK L: Speed of onset, efficacy and tolerability of zolmitriptan nasal spray in the acute treatment of migraine: a randomized, double-blind, placebo-controlled study. CNS Drugs (2005) 19(2):125-136.
   PubMed Web of Science ®Google Scholar
• GAWEL M, ASCHOFF J, MAY A: Zolmitriptan 5 mg nasal spray: efficacy and onset of action in the acute treatment of migraine-results from Phase I of the REALIZE study. Headache (2001) 45:7-16.
   Google Scholar
• DIENER HC, EVERS S: Effectiveness and satisfaction with zolmitriptan 5 mg nasal spray for treatment of migraine in real-life practice: results of a postmarketing surveillance study. Clin. Drug Investig. (2007) 27(1):59-66.
   PubMed Web of Science ®Google Scholar
• BAHRA A, GAWEL MJ, HARDEBO JE, MILLSON D, BREEN SA, GOADSBY PJ: Oral zolmitriptan is effective in the acute treatment of cluster headache. Neurology (2000) 54(9):1832-1839.
   PubMed Web of Science ®Google Scholar
• CITTADINI E, MAY A, STRAUBE A, EVERS S, BUSSONE G, GOADSBY PJ: Effectiveness of intdransal zolmitriptan in acute cluster headache. Arch. Neurol. (2006) 63:1537-1542.
   PubMed Web of Science ®Google Scholar
• RAPOPORT AM, MATHEW NT, SILBERSTEIN SD et al.: Zolmitriptan nasal spray in the acute treatment of cluster headache. Neurology (2007) 69:1-6.
   Google Scholar
• DIENER HC, LIMMROTH V: Acute management of migraine: triptans and beyond. Curr. Opin. Neurol. (1999) 12(3):261-267.
   PubMed Web of Science ®Google Scholar
• HALL GC, BROWN MM, MO J, MACRAE KD: Triptans in migraine: the risks of stroke, cardiovascular disease, and death in practice. Neurology (2004) 62(4):563-568.
   PubMed Web of Science ®Google Scholar
• GOBEL H, PETERSEN-BRAUN M, HEINZE A: Which Properties do Patients Expect of New and Improved Drugs in the Treatment of Primary Headache Disorders? In: Headache treatment: trial methodology and new drugs. Olesen J, Tfelt-Hansen P (Eds), Lippincott-Raven Publishers, New York, USA (1997):93-97.
   Google Scholar
• HALFORD JC, HARROLD JA, LAWTON CL, BLUNDELL JE: Serotonin (5-HT) drugs: effects on appetite expression and use for the treatment of obesity. Curr. Drug Targets (2005) 6(2):201-213.
   PubMed Web of Science ®Google Scholar
• FILLA SA, MATHES BM, JOHNSON KW et al.: Novel potent 5-HT1F receptor agonists: structure-activity studies of a series of substituted N-[3-(1-methyl-4-peperidinyl)-1H-pyrrolo[3,2-b]pyridin-5-yl]amides. J. Med. Chem. (2003) 46(14):3060-3071.
   PubMed Web of Science ®Google Scholar
• WEISSMAN JT, MA JN, ESSEX A, GAO Y, BURSTEIN ES: G-protein-coupled receptor-mediated activation of rap GTPases: characterization of a novel Gαi regulated pathway. Oncogene (2004) 23:241-249.
   PubMed Web of Science ®Google Scholar
• WAINSCOTT DB, JOHNSON KW, PHEBUS LA, SCHAUS JM, NELSON DL: Human 5-HT1F receptor-stimulated [35S] GTPγS binding: correlation with inhibition of guinea pig dural plasma protein extravasation. Eur. J. Pharmacol. (1998) 352(8):117-124.
   PubMed Web of Science ®Google Scholar
• SHEPHEARD S, EDVINSSON L, CUMBERBATCH M et al.: Possible antimigraine mechanisms of action of the 5HT1F receptor agonist LY334370. Cephalalgia (1999) 19(10):851-858.
   PubMed Web of Science ®Google Scholar